Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
RESEARCH TOOLSreports
Holding IKT?
Track your performance easily
IKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.79 - $3.82
Previous Close$1.17
Volume21.73K
Average Volume (3M)25.07K
Market Cap
$8.73M
Enterprise Value$970.78K
Total Cash (Recent Filing)$7.94M
Total Debt (Recent Filing)$177.83K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 11, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.93
Shares Outstanding7,464,070
10 Day Avg. Volume21,490
30 Day Avg. Volume25,073
Standard Deviation0.30
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.72
Price to Sales (P/S)44.18
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.95
Enterprise Value/Gross Profit3.73
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$15.00Price Target Upside1192.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Inhibikase Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe P2 '201' study of risvodetinib in Parkinson's disease continues to progress with high enrollment, indicating a strong interest and potential in the treatment's development.
EarningsInhibikase reports better than expected 1Q24 EPS results.
Product DevelopmentRisvodetinib shows potential in Parkinson’s disease treatment with high brain penetration.
Bears Say
EarningsAnalyst lowers price target to $23 and decreases FY24 EPS estimate.
Financial PerformanceInhibikase reported YE23 results with a net loss of ($19.0M) and ended the period with $13.3M in cash on the balance sheet, and $4.8M ATM remaining.
RisksRisks include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual property challenges.
---
Ownership Overview
72.13%
Insiders
1.80% Mutual Funds
8.12% Other Institutional Investors
17.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $0.79 and its highest was $3.82 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Currently, no data Available
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.01.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 7,464,070 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went down -5.385%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
---
Inhibikase Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (1192.77% Upside)
$15.00 (1192.77% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.02%
12-Months-Change
Fundamentals
Return on Equity
-149.69%
Trailing 12-Months
Asset Growth
-60.50%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson's Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson's disease and the GI complications of Parkinson's disease.
---
IKT Earnings Call
Q2 2024
0:00 / 0:00
---
IKT Stock 12 Month Forecast
Average Price Target
$15.00
▲(1192.77% Upside)
Technical Analysis
Abeona Therapeutics
―
Adaptimmune Therapeutics
―
Actinium Pharmaceuticals
―
Cellectar Biosciences
―
Best Analysts Covering IKT
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-35.03%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -35.03% per trade.
---